The American medical company, Novavax, announced that its vaccine against Covid-19 showed 89.3 percent effectiveness during the third phase of clinical trials.
“The (vaccine) VX-Cove 2373 can play an important role in solving the current global public health crisis,” said Novavax CEO Stanley Erk.
“But the results showed that it is much less effective against the mutated version of Covid-19, which was first detected in South Africa and is spreading rapidly around the world,” he added.
The statement indicated that the company would immediately start developing a new vaccine targeting this mutated version.
Clinical trials conducted in the United Kingdom involved 15,000 people between the ages of 18 and 84, 27 percent of whom were over the age of 65